What Is The Predicted Revenue Outlook For The Global Anti-CD20 Monoclonal Antibodies Market To Surpass $12.05 Billion?
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
What Are The Market Size Estimates For The Anti-CD20 Monoclonal Antibodies Market?
The market size for anti-CD20 monoclonal antibodies has seen a substantial increase in the recent past. It is projected to inflate from $8.33 billion in 2024 to $9.00 billion come 2025, reflecting a compound annual growth rate (CAGR) of 7.9%. The surge during the historic period is linked to the increasing cases of B-cell malignancies, escalating use in the treatment of autoimmune diseases, a rise in FDA and EMA authorizations for newer anti-CD20 therapies, and a mounting global elderly population.
There is projected to be a significant expansion in the anti-CD20 monoclonal antibodies market over the coming years, reaching an estimated value of $12.05 billion in 2029, at a compound annual growth rate (CAGR) of 7.6%. The spur in growth during the prediction period could be due to increased strategic partnerships and licensing agreements, wider use in combination therapies, a growing occurrence of refractory or relapsed cases, rise in healthcare expenditure and access in burgeoning markets, and the acceleration in biosimilar development and approvals. Key trends for the forecast period include progress in monoclonal antibody engineering, the incorporation of anti-CD20 antibodies in combination treatments, customization of cancer therapies powered by technology, advances in subcutaneous and long-acting formulations and emergence of bispecific and next-generation antibodies.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25693&type=smp
Which Industry Forces Are Driving The Anti-CD20 Monoclonal Antibodies Market Forward?
The increase in autoimmune diseases is anticipated to stimulate the expansion of the anti-CD20 monoclonal antibodies market. These diseases arise when the immune system incorrectly perceives the body’s cells as harmful and launches an assault on them. The rise in autoimmune diseases can be attributed to increasing exposure to environmental pollutants, which can negatively affect immune regulation and instigate attacks on the body’s tissues. Anti-CD20 monoclonal antibodies act as a treatment for such diseases by eradicating B cells that contribute to the production of autoantibodies and inflammation, thereby aiding in the regulation of the immune response and curtailing disease symptoms. For example, in June 2024, the Australian Institute of Health and Welfare, a government organization based in Australia, reported that in 2022, approximately 514,000 individuals (2.0%) in Australia were affected by rheumatoid arthritis, a systemic autoimmune disorder, with a prevalence rate of 2.5% among women and 1.6% among men. Consequently, the upsurge in autoimmune diseases is fueling the growth of the anti-CD20 monoclonal antibodies market.
How Is The Anti-CD20 Monoclonal Antibodies Market Organized By Different Segments?
The anti-cd20 monoclonal antibodies market covered in this report is segmented –
1) By Product Type: Rituximab, Obinutuzumab, Ofatumumab, Other Product Types
2) By Route Of Administration: Intravenous, Subcutaneous
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
4) By Application: Non-Hodgkin’s Lymphoma (NHL), Chronic Lymphocytic Leukemia (Cll), Rheumatoid Arthritis, Multiple Sclerosis, Pemphigus Vulgaris, Other Applications
5) By End-User: Hospitals, Surgical Centers and Diagnostic Centers, Maternity Centers, Ambulatory Care Centers, Research And Academia, Other End-Users
Subsegments:
1) By Rituximab: Rituxan, Truxima, Ruxience, Reditux
2) By Obinutuzumab: Gazyva, Biosimilar Candidates
3) By Ofatumumab: Arzerra, Kesimpta
4) By Other Product Types: Ublituximab, Veltuzumab, Ocrelizumab, Mosunetuzumab
What Current And Upcoming Trends Are Shaping The Anti-CD20 Monoclonal Antibodies Market?
Prominent businesses within the anti-CD20 monoclonal antibody market are prioritizing the creation of enhanced products such as obinutuzumab. This innovation specifically targets stubborn or recurring B-cell malignancies more effectively. Obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, is designed to target and eradicate specific B cells involved in certain blood cancers and autoimmune diseases. For instance, Roche, a pharmaceutical company based in Switzerland, announced in March 2025 that a supplemental Biologics License Application (sBLA) for Gazyva/Gazyvaro (obinutuzumab) has been accepted by US Food and Drug Administration (FDA). This acceptance is based on positive results from the Phase III REGENCY study which showed improved complete renal response (CRR) when combined with standard therapy, outperforming standard therapy alone. This distinction establishes Gazyva/Gazyvaro as the solitary anti-CD20 monoclonal antibody showing such positive outcomes in the treatment of lupus nephritis, a severe inflammation triggered by lupus that could lead to kidney failure.
Who Are The Primary Market Leaders In The Anti-CD20 Monoclonal Antibodies Market?
Major companies operating in the anti-cd20 monoclonal antibodies market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, GlaxoSmithKline plc, Amgen Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals, Inc., Chugai Pharmaceutical Co. Ltd., Dr. Reddy’s Laboratories, Genmab A/S, Celltrion Inc., Innovent Biologics, Immunomedics, HLL Lifecare Limited, Shanghai Henlius Biotech Inc., TG Therapeutics, Biogen Idec, Aetos Pharma, Nycomed GmbH
Access The Complete Report Here:
How Do Regional Dynamics Influence The Anti-CD20 Monoclonal Antibodies Market Performance?
North America was the largest region in the Anti-CD20 monoclonal antibodies market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anti-cd20 monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=25693&type=smp
Browse Through More Reports Similar to the Global Anti-CD20 Monoclonal Antibodies Market 2025, By The Business Research Company
Next Generation Antibody Therapeutics Global Market Report 2025
Anti Cancer Mabs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/anti-cancer-mabs-global-market-report
Antibody Discovery Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/antibody-discovery-global-market-report
About The Business Research Company:
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
